The inflammatory bowel disease (IBD) is incurable, chronic, recrudescent disorders in the
inflamed intestines. Current clinic treatments are challenged by systemic exposure-induced …

Vital biomacromolecules, such as RNA, DNA, polysaccharides and proteins, are
synthesized inside cells via the polymerization of small biomolecules to support and multiply …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …

Abnormal activation of the gut mucosal immune system and a highly dysregulated gut
microbiota play essential roles in the progression of inflammatory bowel disease (IBD). The …

Overexpression of classically activated macrophages (M1) subtypes and assessed reactive
oxygen species (ROS) levels are often observed in patients with ulcerative colitis. At present …

Periodontitis is a common type of inflammatory bone loss and a risk factor for systemic
diseases. The pathogenesis of periodontitis involves inflammatory dysregulation, which …

Only a minority of rheumatoid arthritis (RA) patients achieve disease remission, so the
exploration of additional pathogenic factors and the development of new therapeutics are …

Alzheimer's disease (AD) is characterized by amyloid-β accumulation in the brain and
hyperphosphorylated tau aggregation, as well as neuroinflammation. The gut–brain axis has …

While oral probiotics show promise in treating inflammatory bowel disease, the primary
challenge lies in sustaining their activity and retention within the inflamed gastrointestinal …

The exciting success of NBTXR3 in the clinic has triggered a tumult of activities in the design
and development of hafnium-based nanoparticles. However, due to the concerns of …